The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Methotrexate vs MMF with cyclosporine and ATG in MUD transplantation with RIC in patients with AML
Giorgia Battipaglia, MD, Federico II University of Naples, Naples, Italy, summarizes the results of a study comparing the use of methotrexate and mycophenolate mofetil (MMF) in combination with cyclosporine in patients with acute myeloid leukemia (AML) undergoing matched unrelated donor (MUD) transplantation with anti-thymocyte globulin (ATG) prophylaxis and busulfan-fludarabine reduced-intensity conditioning (RIC). The study reported a lower risk of both acute and chronic graft-versus-host disease (GvHD) and a higher probability of GvHD relapse-free survival (GRFS) at two years for patients treated with methotrexate, but there was no difference in relapse incidence, non-relapse mortality (NRM), leukemia-free survival (LFS), and overall survival (OS) between the two patient groups. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
